03:08 PM EDT, 10/31/2024 (MT Newswires) -- Evolus ( EOLS ) said Thursday it has received EU Medical Device Regulation certification for Estyme hyaluronic acid dermal fillers, clearing the path for entry into the European market.

The company said it plans to release Estyme only through select physicians across Europe to gather insights before a full launch in H2 2025.

Evolus ( EOLS ) said it remains on track for US approval and launch of the product, branded as Evolysse, in 2025.

Shares of the company fell nearly 3% in recent trading.

Price: 16.27, Change: -0.48, Percent Change: -2.87